Clinical Trial Update: Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) [Phase 2]

View source ↗

Summary

This Phase 2 trial comparing Vidaza (azacitidine), MGCD0103, and their combination in elderly patients with newly diagnosed acute myeloid leukemia or myelodyspl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• MGCD0103 (mocetinostat)
• VIDAZA (AZACITIDINE)

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | Phase 2 | Status: TERMINATED